These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34084173)

  • 1. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
    Hamilton BA; Wright JF
    Front Immunol; 2021; 12():675897. PubMed ID: 34084173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
    Costa Verdera H; Kuranda K; Mingozzi F
    Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
    Rapti K; Grimm D
    Front Immunol; 2021; 12():753467. PubMed ID: 34777364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
    McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
    Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood.
    Alakhras NS; Moreland CA; Wong LC; Raut P; Kamalakaran S; Wen Y; Siegel RW; Malherbe LP
    Front Immunol; 2024; 15():1354055. PubMed ID: 39007143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to adeno-associated virus vectors.
    Zaiss AK; Muruve DA
    Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
    Tse LV; Moller-Tank S; Asokan A
    Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors.
    Calcedo R; Chichester JA; Wilson JM
    Hum Gene Ther Methods; 2018 Apr; 29(2):86-95. PubMed ID: 29668327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
    Zhu J; Huang X; Yang Y
    J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Immune Sensing of Adeno-Associated Virus Vectors.
    Cao D; Byrne BJ; de Jong YP; Terhorst C; Duan D; Herzog RW; Kumar SRP
    Hum Gene Ther; 2024 Jul; 35(13-14):451-463. PubMed ID: 38887999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical models to assess the immunogenicity of AAV vectors.
    Ertl HCJ
    Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement is an essential component of the immune response to adeno-associated virus vectors.
    Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
    J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
    Ertl HCJ
    Front Immunol; 2021; 12():666666. PubMed ID: 33927727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
    Mays LE; Wilson JM
    Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
    Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
    J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and toxicity of AAV gene therapy.
    Ertl HCJ
    Front Immunol; 2022; 13():975803. PubMed ID: 36032092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.